UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
September 2018
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
Tel: (646) 448-8743
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On September 12, 2018, Akari Therapeutics, Plc, (the “Company”) issued a press release announcing new preclinical rheumatoid arthritis data and new clinical data in patients with Bullous Pemphigoid, highlighting potential advantages of Coversin’s bifunctional activity inhibiting both the complement and leukotriene inflammatory pathways. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The first, third and fifth paragraphs and “Forward Looking Statements” of the press release attached to this Form 6-K are hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.
Exhibit No.
| 99.1 | Press Release dated September 12, 2018. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Akari Therapeutics, Plc |
| | (Registrant) |
| | | |
| | By: | /s/ Clive Richardson |
| | Name: | Clive Richardson |
| | | Interim Chief Executive Officer and
Chief Operating Officer |
| | |
| Date: September 12, 2018 | |
